Veritas In Silico Inc. (JP:130A) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Veritas In Silico Inc. has formed a strategic partnership with Liverpool ChiroChem to accelerate mRNA-targeted drug discovery, leveraging complementary chemistry and biology platforms. The collaboration, which has already shown positive preliminary results, aims to develop first-in-class and best-in-class small molecule drugs. Both companies highlight the strong scientific and cultural fit that contributes to the effectiveness of their joint efforts.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.